fulvestrant has been researched along with Hormone-Dependent Neoplasms in 98 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (15.31) | 18.2507 |
| 2000's | 49 (50.00) | 29.6817 |
| 2010's | 32 (32.65) | 24.3611 |
| 2020's | 2 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Gutgesell, LM; Karumudi, B; Lee, S; Lu, Y; Thatcher, GR; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
| Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J | 1 |
| Corbaux, P; Sabatier, R | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Avogadri-Connors, F; Cutler, RE; Dowsett, M; Guest, SK; Johnston, SR; Lalani, AS; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Rani, A; Ribas, R; Schuster, E; Simigdala, N; Thornhill, A | 1 |
| Cheung, P; Kakit, C; Kiess, N; Parsons, R; Pegno, S; Poulikakos, PI; Schmidt, H; Stratikopoulos, EE; Szabolcs, M; Wu, X | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Giorgetti, C; Huang, X; Im, SA; Liu, Y; Loi, S; Masuda, N; Slamon, DJ; Theall, KP; Turner, NC; Verma, S | 1 |
| Brown, H; Cataldo, ML; Chamness, GC; De Angelis, C; Delpuech, O; Fu, X; Hilsenbeck, SG; Jeselsohn, R; Mitchell, T; Nagi, C; Nardone, A; Osborne, CK; Pilling, M; Rimawi, MF; Schiff, R; Shea, MJ; Trivedi, M; Veeraraghavan, J; Weir, H | 1 |
| Chia, SK; Wilson, S | 1 |
| Bourgeois, H; de Boer, RH; Ferrero, JM; Gansert, JL; Jacot, W; Kaufman, PA; Kennecke, H; Loh, E; McCaffery, I; McGreivy, J; Robertson, JF; Suzuki, S; Zhu, M | 1 |
| Campbell, DC; Johnston, R; McDade, SS; Nugent, S; Panov, KI; Ray, S; Waugh, D | 1 |
| Anur, P; Biswal, NC; Contreras, A; Creighton, CJ; Davies, BR; Fu, X; Giuliano, M; Gray, JW; Guichard, SM; Gutierrez, C; Heiser, LM; Herrera, S; Hilsenbeck, SG; Joshi, A; Karlin, KL; Klinowska, T; Kumar, V; Lee, AV; Mills, GB; Morrison, G; Nanda, S; Nardone, A; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Smith, PD; Spellman, P; Wang, T; Westbrook, TF | 1 |
| Abramson, V; Allen, EV; Arteaga, CL; Bafna, S; Balko, JM; Bhola, NE; Dugger, TC; Estrada, MV; Giltnane, JM; Jansen, VM; Mayer, I; Meszoely, I; Sanders, M; Ye, F | 1 |
| Cheng, J; Hong, Q; Jia, X; Lei, L; Li, D; Li, J; Liu, G; Mo, M; Shao, Z; Shen, Z; Wang, Y | 1 |
| Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R | 1 |
| Goodwin, A; Lee, CI; Wilcken, N | 1 |
| Buijs, C; de Vries, EG; Mourits, MJ; Willemse, PH | 1 |
| Aiyar, S; Fan, P; Kim, TH; Li, Y; Santen, RJ; Wang, JP; Yue, W | 1 |
| Cheng, P; Hershberger, PA; Kanterewicz, B; Liu, Y; McCarty, KS; Nichols, M | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Amoroso, D; Camerini, A; Donati, S; Garrone, O; Mattiot, VP; Porta, RP; Puccetti, C; Puccinelli, P; Rondini, M; Sgambato, A; Siclari, O; Tartarelli, G; Valsuani, C; Vincenti, M | 1 |
| Conte, P; Frassoldati, A; Guarneri, V | 1 |
| Badve, S; Bhat-Nakshatri, P; McCune, K; Nakshatri, H; Nephew, KP; Thorat, MA | 1 |
| Alberola Candel, V; Gasent Blesa, JM; Giner Marco, V; Giner-Bosch, V; Laforga Canales, JB; Provencio Pulla, M | 1 |
| Alvarez, EA; Azzam, D; Chen, Y; Guggisberg, N; Hennessy, BT; Jordà, M; Ju, Z; Slingerland, JM; Wander, SA | 1 |
| Beckman, BS; Bratton, MR; Burow, ME; Collins-Burow, BM; Curiel, TJ; Dent, P; Elliott, S; Fonseca, JP; Fuqua, SA; Horton, LW; Hung, MC; Muir, SE; Neel, NF; Nephew, KP; Rhodes, LV; Richmond, A; Salvo, VA; Segar, C; Short, SP; Sobolik-Delmaire, T; Sun, M; Tilghman, SL; Wadsworth, S; Wei, Y; Wood, CE; Worthylake, RA; Yu, D; Zaja-Milatovic, S; Zhu, Y | 1 |
| Aubé, M; Ayotte, P; Larochelle, C | 1 |
| Croxtall, JD; McKeage, K | 1 |
| Coombes, RC; Januszewski, A; Palmieri, C; Stanway, S | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Arteaga, CL; Balko, JM; Buck, E; Fox, EM; González-Angulo, AM; Kuba, MG; Liu, S; Manning, HC; Miller, TW; Mills, GB; Sánchez, V; Shyr, Y; Smith, RA; Ye, F | 1 |
| de Cremoux, P | 1 |
| Anderson, E; Badwe, RA; Bines, J; Emeribe, UA; Finlay, P; Gee, JM; Harbeck, N; Hegg, R; Kuter, I; Lowe, ES; Nicholson, RI; Sapunar, F; Singer, CF | 1 |
| Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F | 1 |
| Giulianelli, S; Gutkind, JS; Helguero, LA; Lamb, CA; Lanari, C; Martins, R; Molinolo, AA; Soldati, R; Vanzulli, SI; Vaqué, JP; Wargon, V; Zeitlin, E | 1 |
| Bago-Horvath, Z; Bartsch, R; Berghoff, A; DeVries, C; Dubsky, P; Fitzal, F; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Zielinski, CC | 1 |
| Harada, A; Li, C; Oh, Y | 1 |
| Aapro, M; Bischoff, J; Brain, E; Cardoso, F; Lück, HJ; Tanner, M; Tjan-Heijnen, VC; Zotano, ÁG | 1 |
| Ishitobi, M; Yagi, T; Yoshinami, T | 1 |
| Brodie, AM; Jelovac, D; Long, BJ; Thiantanawat, A | 1 |
| Jordan, VC; Lee, ES; Takei, H | 1 |
| Calligé, M; Chailleux, C; Giamarchi, C; Richard-Foy, H; Rochaix, P; Trouche, D | 1 |
| Balkenende, A; Bindels, EM; Lallemand, F; Michalides, R; Verwoerd, D | 1 |
| Bogart, DF; Castañeda, JM; Li, P; Lupu, R; Tsai, MS | 1 |
| Bigsby, RM; Fan, M; Nephew, KP | 1 |
| Banerjee, S; Banerjee, SK; Saxena, N; Sengupta, K | 1 |
| Chaouat, M; Forgez, P; Gompel, A; Jacob, D; Perrot, JY; Rostène, W; Somaï, S | 1 |
| Boester, M; Diedrich, K; Frey, N; Ortmann, O; Porz, S; Treeck, O; Weber, A | 1 |
| Albanese, C; Cai, D; Chernoff, J; Felekkis, KN; Iyer, A; Lerner, A; Luo, Z; Near, RI; Pestell, RG | 1 |
| Amant, F; Joubert, A; Lindeque, BG; Lottering, ML; Thaver, V; Vergote, I | 1 |
| Brockdorff, BL; Heiberg, I; Lykkesfeldt, AE | 1 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Colomer, R; Lupu, R; Menendez, JA | 1 |
| Koeberle, D; Perey, L; Thuerlimann, B | 1 |
| Possinger, K | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Jazieh, AR; Nahleh, ZA | 1 |
| Kilker, RL; Planas-Silva, MD; Waltz, PK | 1 |
| Bhattacharyya, RS; Feldman, D; Krishnan, AV; Swami, S | 1 |
| Amant, F; Berteloot, P; Leunen, K; Neven, P; Van Gorp, T; Vergote, I | 1 |
| Clément, P; Dietrich, D; Fiche, M; Goldhirsch, A; Hawle, H; Köberle, D; Nolé, F; Paridaens, R; Perey, L; Thürlimann, B; Wildiers, H; Zaman, K | 1 |
| Ariazi, EA; Ariazi, JL; Cordera, F; Gill, SD; Jordan, VC; Kim, HR; Lewis-Wambi, JS; Li, T; Pyle, JR; Sharma, CG; Shupp, HA | 1 |
| De Stefano, I; Fabrizi, M; Ferlini, C; Gallo, D; Mantuano, E; Mozzetti, S; Scambia, G | 1 |
| Carcel-Trullols, J; Evans, TT; Higuchi, M; Mizumachi, T; Naito, A; Xie, CH | 1 |
| Dixon, JM; Faratian, D; Macaskill, EJ; Renshaw, L; Thomas, JS; White, S; Young, OE | 1 |
| Bradley, LM; Gierthy, JF; Pentecost, BT | 1 |
| Body, JJ; Journé, F; Laurent, G; Leclercq, G | 1 |
| Dive, C; Hickman, JA; Morris, ID; Wakeling, AE; Wilson, JW | 1 |
| Briand, P; Larsen, SS; Lykkesfeldt, AE | 1 |
| Dowsett, M; Iveson, TJ; Johnston, SR; Smith, IE | 1 |
| Anderson, E; Bell, J; DeFriend, DJ; Howell, A; Mansel, RE; West, CM; Wilks, DP | 1 |
| Briand, P; Lykkesfeldt, AE; Madsen, MW | 1 |
| Brünner, N; Clarke, R; Coopman, P; Derocq, D; Garcia, M; Rochefort, H | 1 |
| Jordan, VC; Pink, JJ | 1 |
| Benedetti Panici, P; Bonanno, G; de Vincenzo, R; Ercoli, A; Fattorossi, A; Isola, G; Mancuso, S; Pernisco, S; Scambia, G | 1 |
| Anderson, E; Blamey, RW; Clarke, R; Dowsett, M; Gee, JM; Howell, A; Manning, DL; McClelland, RA; Nicholson, RI; Robertson, JF; Wakeling, AE | 1 |
| Afshari, CA; Annab, LA; Barrett, JC; Risinger, JI; Romagnolo, D; Terry, LA; Thompson, TE | 1 |
| Akinaga, S; Kurebayashi, J; Kurosumi, M; Nakata, T; Otsuki, T; Sonoo, H; Yamamoto, S | 1 |
| Williams, GM | 1 |
| Chun, TY; Gorski, J | 1 |
| Huper, G; Iglehart, JD; Lobenhofer, EK; Marks, JR | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q | 1 |
| Archer, C; Assersohn, L; Boeddinghaus, I; Chang, J; Dowsett, M; Ellis, PA; Gregory, RK; Johnston, SR; Mainwaring, P; Powles, TJ; Salter, J; Smith, IE | 1 |
| Atkin, SL; Eycott, K; Green, V; Newton, CJ | 1 |
| Addeo, R; Altucci, L; Belsito Petrizzi, V; Boccia, V; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Pacilio, C; Salzano, S; Weisz, A | 1 |
| Conrad, SE; Varma, H | 1 |
| Eischeid, A; Jeng, MH; Santen, RJ; Wang, JP; Yue, W | 1 |
| Kunselman, AR; Legro, RS; Miller, SA; Satyaswaroop, PG | 1 |
| Emery, JG; Fisher, PW; Gowen, M; Kingsbury, WD; Nadeau, DP; Nicholson, TA; Nuttall, ME; Pendrak, I; Suva, LJ; Zhu, Y | 1 |
| Ahmed, Y; Bentrem, DJ; Chisamore, MJ; Jordan, VC; Tonetti, DA | 1 |
| Parker, MG; Soulez, M | 1 |
| Beckman, BS; Burow, ME; McLachlan, JA; Tang, Y; Weldon, CB | 1 |
| Bogart, DF; Li, P; Lupu, R; Mehmi, I; Tsai, MS | 1 |
| Jeng, MH; Masamura, S; McPherson, R; Santen, R; Santner, S; Shim, WS; Song, R; Wang, JP; Yue, W | 1 |
| Robertson, JF | 1 |
| Chrysogelos, SA; Wilson, MA | 1 |
| Bouker, KB; Brünner, N; Clarke, R; Davis, N; Gu, Z; Lee, RY; Leonessa, F; Liu, A; Lu, J; Skaar, TC; Wang, Y; Welch, JN; Zhu, Y | 1 |
| Bowler, J; Wakeling, AE | 1 |
15 review(s) available for fulvestrant and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles; United States | 2015 |
Fulvestrant for hormone-sensitive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2017 |
The influence of endocrine treatments for breast cancer on health-related quality of life.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Mastectomy; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome | 2008 |
Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen | 2011 |
Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Dehydroepiandrosterone Sulfate; Estradiol; Estrone; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Steryl-Sulfatase; Sulfonic Acids; Tamoxifen | 2011 |
[Hormone therapy and breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Tamoxifen | 2013 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent | 2006 |
Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2008 |
Clinical studies of apoptosis and proliferation in breast cancer.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Biomarkers; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Pregnancy; Tamoxifen; Tumor Cells, Cultured | 1999 |
Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
Topics: Adaptation, Physiological; Animals; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Biological; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Proteins; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transplantation, Heterologous; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2001 |
Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Down-Regulation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2001 |
Development of novel oestrogen-receptor antagonists.
Topics: Animals; Breast Neoplasms; Drug Design; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Tamoxifen | 1991 |
9 trial(s) available for fulvestrant and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Estrogens; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Progesterone; Progression-Free Survival; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Topics: Aged; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Postmenopause; Receptor, ErbB-2 | 2013 |
Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol; Cholesterol, LDL; Endometrium; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Lipid Metabolism; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Postmenopause; Progesterone; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Triglycerides | 2009 |
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2012 |
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Recurrence; Triazoles | 2012 |
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Goserelin; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Premenopause | 2012 |
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Salvage Therapy; Treatment Outcome | 2007 |
Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Ki-67 Antigen; Middle Aged; Neoplasms, Hormone-Dependent; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2008 |
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Tamoxifen | 1995 |
74 other study(ies) available for fulvestrant and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice, Nude; Models, Molecular; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes | 2017 |
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Drug Administration Schedule; Estrogens; Fatigue; Febrile Neutropenia; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Mucositis; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Thrombocytopenia | 2020 |
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Male; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2020 |
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Estrogens; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Neoplasms, Hormone-Dependent; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen | 2018 |
Mouse ER+/PIK3CA
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cocarcinogenesis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knock-In Techniques; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Mutation, Missense; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neuropeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides; Thiazoles | 2019 |
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Heterografts; Humans; Indoles; MCF-7 Cells; Mice; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2019 |
IGF-1R inhibition: right direction, wrong pathway?
Topics: Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent | 2013 |
Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
Topics: Androgen Antagonists; Androgens; Anilides; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Male; MCF-7 Cells; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Ribosomes; RNA, Neoplasm; RNA, Ribosomal; Signal Transduction; Tosyl Compounds; Transcription, Genetic | 2013 |
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Doxycycline; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Breast Neoplasms; Cell Cycle Proteins; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Random Allocation; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Xenograft Model Antitumor Assays | 2015 |
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Letrozole; MAP Kinase Signaling System; Mice; Mice, Nude; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Nitriles; Postmenopause; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Transcription, Genetic; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Receptors, Estrogen; Tamoxifen; Tissue Distribution; Tumor Cells, Cultured | 2009 |
Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
Topics: Adenocarcinoma; Amino Acid Motifs; Amino Acid Substitution; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Point Mutation; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factor AP-1; Transfection | 2010 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Inflammation; Lipid Metabolism; Liver; Menopause; Neoplasms, Hormone-Dependent; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators | 2009 |
Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Fulvestrant; GATA3 Transcription Factor; Gene Regulatory Networks; Hepatocyte Nuclear Factor 3-alpha; Humans; Insulin; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prognosis; T-Box Domain Proteins; Tamoxifen; Transcription, Genetic | 2010 |
Experience with fulvestrant acetate in castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Castration; Combined Modality Therapy; Estradiol; Fulvestrant; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms | 2010 |
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; G1 Phase; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Quinazolines; src-Family Kinases; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Receptors, CXCR4; Receptors, Estrogen | 2011 |
Differential effects of a complex organochlorine mixture on the proliferation of breast cancer cell lines.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dihydrotestosterone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Hydrocarbons, Chlorinated; Neoplasms, Hormone-Dependent; Receptors, Androgen; Regression Analysis | 2011 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein-Tyrosine Kinases; Pyrazines; Random Allocation; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays | 2011 |
Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
Topics: Animals; Breast Neoplasms; Cell Growth Processes; Cell Nucleus; Cyclin D1; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Humans; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Receptors, Progesterone | 2012 |
IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Caspase 7; Cell Line, Tumor; DNA, Complementary; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Library; Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Interaction Mapping; Tamoxifen; Two-Hybrid System Techniques | 2012 |
[Endocrine therapy for advanced breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2002 |
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Lymphokines; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells.
Topics: Blotting, Western; Cell Nucleus; Chromatin; Deoxyribonuclease I; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation; Humans; Immunohistochemistry; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Proteins; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Cycle Proteins; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; DNA-Binding Proteins; E2F Transcription Factors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; G1 Phase; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proto-Oncogene Proteins; Receptors, Estrogen; Recombinant Fusion Proteins; S Phase; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2002 |
Cyr61 promotes breast tumorigenesis and cancer progression.
Topics: Adenocarcinoma; Breast Neoplasms; Collagen; Cysteine-Rich Protein 61; Disease Progression; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Endothelial Growth Factors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Laminin; Lymphokines; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proteoglycans; Receptors, Estrogen; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Immunoblotting; Multienzyme Complexes; NEDD8 Protein; Neoplasms, Hormone-Dependent; Proteasome Endopeptidase Complex; Receptors, Estrogen; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Ubiquitin-Activating Enzymes; Ubiquitins | 2003 |
Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Line, Tumor; Cycloheximide; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Synthesis Inhibitors; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transfection; Vascular Endothelial Growth Factor A | 2003 |
Antiestrogens are pro-apoptotic in normal human breast epithelial cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Breast; Breast Neoplasms; Caspase 3; Caspases; Cells, Cultured; Enzyme Induction; Epithelial Cells; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, p53; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Stimulation, Chemical; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
H-ras dependent estrogenic effects of epidermal growth factor in the estrogen-independent breast cancer cell line MDA-MB-231.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Epidermal Growth Factor; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Response Elements | 2003 |
AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Animals; Breast Neoplasms; Carrier Proteins; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cyclin D1; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Guanine Nucleotide Exchange Factors; Humans; Mice; Molecular Sequence Data; Neoplasms, Hormone-Dependent; NIH 3T3 Cells; p21-Activated Kinases; Promoter Regions, Genetic; Protein Biosynthesis; Protein Serine-Threonine Kinases; Proteins; Rabbits; rac1 GTP-Binding Protein; Transfection | 2003 |
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.
Topics: Antineoplastic Agents, Hormonal; Carcinosarcoma; Cell Cycle; Cell Division; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Progesterone; Raloxifene Hydrochloride; Tamoxifen; Triptorelin Pamoate; Uterine Neoplasms | 2003 |
Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
Topics: Blotting, Western; Breast Neoplasms; Cell Fusion; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Flow Cytometry; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 2; Microscopy, Phase-Contrast; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2003 |
Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses e
Topics: Breast Neoplasms; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; gamma-Linolenic Acid; Humans; Luciferases; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
Re: Playing the old piano: another tune for endocrine therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Forecasting; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Women's Health | 2004 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gefitinib; Humans; Mice; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Trastuzumab; Tumor Cells, Cultured; Tumor Escape; Xenograft Model Antitumor Assays | 2005 |
Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 2006 |
Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Topics: Androgens; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 2006 |
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Selective Estrogen Receptor Modulators | 2006 |
Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Glycine max; Humans; Kallikreins; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Organ Size; Phytoestrogens; Plant Extracts; RNA, Messenger; Thrombospondin 1; Uterus; Xenograft Model Antitumor Assays | 2007 |
Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Blotting, Southern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; DNA, Mitochondrial; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Ethidium; Female; Flow Cytometry; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2008 |
Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line.
Topics: Base Sequence; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Neoplasms, Hormone-Dependent; Phenotype; Receptor, IGF Type 1; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Somatomedins | 2008 |
MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Death; Cell Division; Cell Survival; DNA Damage; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Etoposide; Fulvestrant; Humans; Mechlorethamine; Neoplasms, Hormone-Dependent; Tumor Cells, Cultured | 1995 |
Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1995 |
Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Division; Clone Cells; Culture Media, Serum-Free; Drug Resistance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Pleural Effusion, Malignant; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1994 |
Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Topics: Animals; Base Sequence; Breast Neoplasms; Cell Division; Chloramphenicol O-Acetyltransferase; Culture Media; Drug Resistance; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Time Factors; Transfection; Tumor Cells, Cultured | 1994 |
Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cathepsin D; Cell Division; Drug Resistance; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proteins; Receptors, Estrogen; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1994 |
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Ductal, Breast; DNA, Neoplasm; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hydroxytestosterones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Binding; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1996 |
Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Flow Cytometry; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Phenotype; Progesterone; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1996 |
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proteins; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins | 1996 |
Estrogen upregulation of BRCA1 expression with no effect on localization.
Topics: Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Receptors, Estrogen; RNA, Messenger; Stimulation, Chemical; Tumor Cells, Cultured; Up-Regulation | 1998 |
A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; DNA Primers; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured; Up-Regulation | 1998 |
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Transformation, Neoplastic; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mice; Neoplasms, Hormone-Dependent; Tamoxifen; Toremifene | 1999 |
High concentrations of bisphenol A induce cell growth and prolactin secretion in an estrogen-responsive pituitary tumor cell line.
Topics: Animals; Antineoplastic Agents; Benzhydryl Compounds; Cell Division; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Fulvestrant; Neoplasms, Hormone-Dependent; Phenols; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344; Receptors, Estrogen; Secretory Rate; Tumor Cells, Cultured | 2000 |
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
Topics: Adenocarcinoma; Androstadienes; Breast Neoplasms; Butadienes; Chromones; Culture Media, Serum-Free; Cyclic AMP-Dependent Protein Kinases; Cyclin D1; Depression, Chemical; DNA Replication; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Flavonoids; Fulvestrant; Humans; Isoquinolines; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mitosis; Morpholines; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Retinoblastoma Protein; Sulfonamides; Wortmannin | 2000 |
Aromatase inhibitors and their antitumor effects in model systems.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Mice; Mice, Inbred BALB C; Models, Biological; Neoplasms, Hormone-Dependent; Tamoxifen; Transfection | 1999 |
Response of estrogen receptor containing tumour cells to pure antiestrogens and the calmodulin inhibitor, calmidzolium chloride.
Topics: Breast Neoplasms; Calmodulin; Cell Death; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Pituitary Neoplasms; Receptors, Estrogen; Tumor Cells, Cultured | 2000 |
The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cyclin-Dependent Kinases; Cyclins; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Retinoblastoma Protein; Tumor Cells, Cultured | 2000 |
Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain.
Topics: Adenocarcinoma; Antigens, Polyomavirus Transforming; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; G1 Phase; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Structure, Tertiary; Recombinant Fusion Proteins; Retinoblastoma Protein; Tamoxifen; Transfection; Tumor Cells, Cultured | 2000 |
Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Flavonoids; Fulvestrant; Humans; MAP Kinase Signaling System; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Thymidine; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation | 2000 |
Role of androgens in the growth of endometrial carcinoma: an in vivo animal model.
Topics: Androgens; Animals; Aromatase; Blotting, Western; Carcinoma; Disease Models, Animal; Electrophoresis, Agar Gel; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Regression Analysis; Testosterone; Transplantation, Heterologous | 2001 |
Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Endometrium; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tumor Cells, Cultured | 2001 |
Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Protein Kinase C; Protein Kinase C-alpha; Receptors, Estrogen; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2001 |
Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, bcl-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Paclitaxel; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
Expression and regulation of Cyr61 in human breast cancer cell lines.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Breast Neoplasms; Calcitriol; Cysteine-Rich Protein 61; Drug Resistance; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Immediate-Early; Growth Substances; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Protein Structure, Tertiary; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators; Tamoxifen; Tetradecanoylphorbol Acetate; Transcriptional Activation; Transfection; Tretinoin; Tumor Cells, Cultured | 2002 |
Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells.
Topics: Breast Neoplasms; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Introns; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Topics: Animals; Breast Neoplasms; Cyclic AMP Response Element-Binding Protein; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-1; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; NF-kappa B; Nuclear Proteins; Nucleophosmin; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Signal Transduction; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2002 |